AXL and pancreatic neoplasm: So far many studies have focused on the cancer-cell autonomous role of Gas6 and based on their effect on tumor cell proliferation and plasticity several inhibitors of the Gas6-Axl pathways, including warfarin (clinical trial ID: NCT03536208) are currently being tested in pancreatic cancer patients.